ClinicalTrials.gg
CompletedNCT03264079Updated May 29, 2025

Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults

A Phase 1 interventional study of Bardoxolone methyl capsules 10 mg and Itraconazole capsules 100 mg in Healthy Volunteers, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2017, 9 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This trial will study the impact of a strong CYP3A4 inhibitor (itraconazole) on the pharmacokinetics of bardoxolone methyl (RTA 402) in healthy adult subjects.

This is an open-label, fixed-sequence crossover pharmacokinetic (PK) study in healthy volunteers.

Subjects will complete a screening visit within 28 days of Study Day 1. Subjects must qualify for the study based on inclusion/exclusion criteria. For Period 1, all qualified subjects shall receive a single oral dose of bardoxolone methyl (10 mg) on Day 1. For Period 2, following a washout of 14 days, itraconazole (SPORANOX®) capsules (100 mg) will be administered as a 200-mg single daily dose on Study Days 15 through 27, with bardoxolone methyl (10 mg) administered on Day 18 (1 hour after itraconazole administration).

Bardoxolone methyl doses will be administered under fasted conditions. Itraconazole will be administered under fed conditions on Study Days 15-17, and Study Days 19-27.

On study Day 18, itraconazole will be administered under fasted conditions. Subjects will be confined beginning on Study Day -1 through the last blood sample collection on Study Day 9 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 28 during Period 2.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • RTA 402
  • Bardoxolone methyl
  • Itraconazole
  • Sporanox
  • CYP3A4
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female and age is between 18 and 55 years, inclusive;
  • Female subjects of must not be planning a pregnancy, pregnant, or lactating, and must have a negative serum pregnancy test result before enrollment into the study, and must be willing to use as specified or abstain from sexual activity for the duration of the study;
  • If male, subject must be surgically sterile or practicing an approved method of contraception, from initial study drug administration through 90 days after administration of the last dose of study drug;
  • If male, subject agrees to abstain from sperm donation through 90 days after administration of the last dose of study drug;
  • (BMI) is ≥ 18 to ≤31 kg/m2, inclusive;
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead (ECG), as judged by the investigator;
  • Must voluntarily sign and date each , approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  • History of drug allergies, including allergies to any of the components of the product and/or clinically significant food allergies as determined by the investigator;
  • Presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease, as determined by the investigator;
  • Presence of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines;
  • Known to any component in the formulations of bardoxolone methyl, or SPORANOX®;
  • Requirement for any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements on a regular basis;
  • Use of any medications (over-the-counter and/or prescription medication), vitamins, and/or herbal supplements, within the 30-day period prior to study drug administration or within 5 half-lives (if known), whichever is longer;
  • Recent (6-month) history of drug or alcohol abuse;
  • B-type natriuretic peptide (BNP) level >200 pg/mL at screening;
  • Positive test result for surface antigen (HBsAg), virus antibody (HCV Ab), or antibodies (HIV Ab) at screening;
  • Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration;
  • Receipt of any investigational product within a time period equal to 10 half-lives of the product, if known, or a minimum of 30 days prior to study drug administration;
  • Positive screen results for drugs of abuse, alcohol, or cotinine at screening or Day -1;
  • Consumption of alcohol within 72 hours prior to study drug administration;
  • Consumption of grapefruit, grapefruit products, star fruit, star fruit products, or Seville oranges within the 72-hour period prior to study drug administration;
  • Use of tobacco or nicotine-containing products within the 6-month period preceding study drug administration;
  • Current enrollment in another clinical study;
  • Screening laboratory analyses that show any of the following abnormal laboratory results:

    1. (ALT) or aspartate aminotransferase (AST) levels above the (ULN);
    2. Clinically significant abnormal ; ECG with using Fridericia's correction formula (QTcF) > 450 msec is exclusionary;
    3. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive either bardoxolone methyl or itraconazole.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Bardoxolone methyl 10 mg and Itraconazole 200 mg

    Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg

    Drug: Bardoxolone methyl capsules 10 mg · Drug: Itraconazole capsules 100 mg

Interventions

  • DrugBardoxolone methylStudies of Bardoxolone methylBardoxolone methyl pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial

    Also known as: RTA 402

  • DrugItraconazole capsules 100 mg

    Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial

    Also known as: Sporanox

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve of bardoxolone methyl from time 0 to the last measurable time point (AUC0-t).

    Time frame: 28 days

  2. Area under the plasma concentration-time curve of bardoxolone methyl extrapolated to infinity (AUC0-inf)

    Time frame: 28 days

  3. Maximum observed drug concentration (Cmax) in plasma of bardoxolone methyl

    Time frame: 28 days

07

Study locations

1 site
  • Medpace Clinical Pharmacology Unit
    Cincinnati, Ohio 45227, United States
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Nov 2017, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2017
First posted
Aug 28, 2017
StartActual
Oct 16, 2017
Primary completionActual
Nov 13, 2017
CompletionActual
Nov 13, 2017
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03264079
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Aug 28, 2017
Start date
Oct 16, 2017
Primary completion
Nov 13, 2017
Completion
Nov 13, 2017
Last update
May 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bardoxolone methyl

Start the discussion